Neurocrine Biosciences, Inc. NBIX
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About NBIX
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Neurocrine Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company operates within the biotechnology and specialty pharmaceutical industries, with a primary emphasis on central nervous system (CNS) diseases and endocrine-related conditions. Its principal revenue driver is INGREZZA (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor approved for tardive dyskinesia and chorea associated with Huntington’s disease. The company also generates collaboration and licensing revenue through partnerships with larger pharmaceutical companies.
Neurocrine Biosciences serves neurologists, psychiatrists, movement disorder specialists, endocrinologists, and specialty healthcare providers primarily in the United States, while maintaining development and partnership activities internationally. The company has positioned itself as a focused neuroscience innovator with expertise in movement disorders, neuropsychiatry, and rare endocrine diseases. Founded in 1992 and headquartered in San Diego, California, Neurocrine evolved from an early-stage neuroscience research company into a commercially successful biotechnology firm following the launch and expansion of INGREZZA and subsequent pipeline development activities.
Business Operations
Neurocrine Biosciences primarily operates through a single integrated biotechnology business focused on research, development, and commercialization of CNS-related therapeutics. Revenue is generated mainly through product sales, particularly from INGREZZA, along with milestone payments, royalty revenue, and collaborative arrangements. The company also markets and develops therapies associated with endocrine disorders, including products and candidates originating from partnerships involving AbbVie, Takeda, and other biotechnology firms. Key pipeline programs include treatments targeting schizophrenia, congenital adrenal hyperplasia, major depressive disorder, epilepsy-related conditions, and movement disorders.
The company’s operations are concentrated in the United States, where its commercial infrastructure is based, though it maintains licensing and development relationships internationally. Neurocrine controls proprietary drug discovery platforms focused on neuroscience and endocrine biology, including expertise in VMAT2 inhibition and selective receptor modulation. Important collaborations include partnerships with Takeda Pharmaceutical Company, AbbVie, and Voyager Therapeutics. The company has also expanded through strategic licensing arrangements and research alliances intended to strengthen its late-stage clinical pipeline and long-term commercial portfolio.
Strategic Position & Investments
Neurocrine Biosciences has strategically focused on expanding its neuroscience franchise while diversifying beyond a single commercial product. Growth initiatives include lifecycle expansion for INGREZZA, advancement of next-generation neuropsychiatric therapies, and investment in rare disease and endocrinology programs. The company has committed substantial capital toward clinical-stage assets involving muscarinic receptor agonists, gene therapy collaborations, and precision neuroscience approaches. Neurocrine has also pursued external innovation through licensing agreements and milestone-based partnerships rather than large-scale acquisitions.
Among notable investments are collaborations involving Voyager Therapeutics for gene therapy applications targeting neurological diseases and partnerships supporting treatments for schizophrenia and mood disorders. Neurocrine has also invested in selective receptor modulation technologies and biologically targeted CNS therapeutics intended to address unmet medical needs in psychiatry and neurology. The company’s strategic positioning is supported by its commercial cash flow from INGREZZA, allowing continued internal research investment and external business development activity without reliance on broad diversification outside neuroscience.
Geographic Footprint
Neurocrine Biosciences is headquartered in San Diego, California, and maintains its primary commercial and operational presence in the United States. The company’s marketed products are predominantly sold in the U.S. healthcare market, which represents the vast majority of its revenue base. Its research, clinical development, regulatory affairs, and corporate functions are also largely U.S.-centered.
Internationally, Neurocrine participates through licensing agreements, development collaborations, and strategic partnerships spanning Europe, Asia-Pacific, and other global pharmaceutical markets. While the company does not maintain the same level of direct commercial infrastructure overseas as larger multinational pharmaceutical companies, its alliances with global partners extend its operational influence internationally. Clinical trials and regulatory activities associated with pipeline candidates also involve multinational participation across several geographic regions.
Leadership & Governance
Neurocrine Biosciences was founded by a group of scientists and biotechnology entrepreneurs focused on neuroscience and endocrine disorders. The company’s leadership strategy has emphasized scientific specialization, disciplined commercial execution, and long-term investment in CNS innovation. Corporate governance is overseen by a board of directors and executive leadership team with experience in biotechnology research, commercialization, finance, and regulatory operations.
Key executives include:
- Kyle Gano, Ph.D. – Chief Executive Officer
- Matt Abernethy – Chief Financial Officer
- Eamonn P. Hobbs – Chairman of the Board
- Eric Benevich – Chief Commercial Officer
- Jude Onyia, M.D. – Chief Medical Officer
- Chris O’Brien – Chief Legal Officer
Leadership has consistently communicated a strategic vision centered on building a leading neuroscience-focused biopharmaceutical company through targeted R&D investment, commercialization excellence, and selective partnerships. Public disclosures in SEC filings, investor presentations, and earnings materials emphasize sustainable growth through pipeline diversification and continued expansion within CNS therapeutics.